Major EU funding awarded to HUS Helsinki University Hospital led research project to study the role of systemic endotoxemia as driver of chronic inflammation in arthritis
15.12.2022 10:29:19 EET | HUS | Press release

The EU main call objective was to develop a personalized blueprint to reduce chronic inflammation and to prevent health-to-disease transition.
“In this project, we aim to explore the relationship between gut microbiota, intestinal permeability, and systemic endotoxemia. Further we aim to understand their role as drivers of disease onset and disease activity in rheumatoid arthritis, osteoarthritis and spondyloarthritis. The findings of the four-year research consortium may lead to the identification and development of novel preventive and therapeutic approaches,” says ENDOTARGET project leader, Professor Kari Eklund from HUS.
The HUS-led consortium studies will include cohort and register studies, cell molecular functional studies, clinical and diet intervention studies in the rheumatic diseases.
“Moreover, by combining all this data, a machine learning (ML) and AI-informed rheumatic disease prediction tool (RDPT) will be developed for clinicians to help them identify patients with increased risk of developing the target diseases,” concludes Eklund.
The ENDOTARGET-consortium will also empower citizens and patients to be able to manage better their own physical health and well-being by testing a new evidence-based model linking nutrition knowledge, termed “Clinical culinary”, and application of dietary strategies to health promotion and reduction of disease activity of rheumatic diseases.
Apart from HUS, the Consortium consists of several leading European research organizations, such as the University of Helsinki, and research groups from Switzerland, Portugal, Spain, Italy, Austria, and Estonia. The consortium also includes industry partners, specialized in bioinformatics, artificial intelligence, machine learning, and communications. The proposal preparation was supported by company specialized in EU-funding, namely Spinverse.
The ENDOTARGET Consortium: Coordinator HUS Helsinki University Hospital (Finland), University of Helsinki (Finland), University of Tartu, University of Campania “L. Vanvitelli”, University of Lisbon (Portugal), Galician Health Service (SERGAS) (Spain), Technical University of Vienna (Austria), Swiss Federal Institute of Technology (ETH Zurich) (Switzerland), Swiss Institute of Bioinformatics (Switzerland), Biomedical Research Institute of Salerno (Italy), NEC Laboratories Europe GmbH (Germany), Steinbeis 2i GmbH (Germany).
For more information:
Professor, Chief Physician Kari Eklund
HUS Helsinki University Hospital
Tel. +358 50 427 0123
kari.eklund@hus.fi
Senior Researcher Gonçalo Barreto
HUS Helsinki University Hospital
goncalo.barreto@helsinki.fi
Keywords
Images

About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Blodprov underlättar diagnostiken av lymfkörtelinflammationer i halsområdet hos barn1.7.2026 08:54:42 EEST | Pressmeddelande
En studie som genomförts vid HUS har bekräftat tillförlitligheten hos en blodprovsbaserad diagnostisk metod för lymfkörtelinflammationer i halsområdet hos barn som orsakas av miljömykobakterier. Ett blodprov är ett snabbare och för patienten mer skonsamt sätt att säkerställa diagnosen än invasiva metoder, såsom vävnadsprovtagning.
Verikoe helpottaa lasten kaulan alueen imusolmuketulehdusten diagnostiikkaa1.7.2026 08:54:42 EEST | Tiedote
HUSissa tehdyssä tutkimuksessa todennettiin verikokeeseen perustuvan diagnostisen menetelmän luotettavuus ympäristömykobakteerien aiheuttamissa lasten kaulan alueen imusolmuketulehduksissa. Verikoe on nopeampi ja potilaalle miellyttävämpi tapa varmistaa diagnoosi kuin kajoavat menetelmät, kuten koepalan otto.
A blood test aids the diagnosis of cervical lymphadenitis in children1.7.2026 08:54:42 EEST | Press release
A study conducted at HUS confirmed the reliability of a blood test-based method for diagnosing cervical lymphadenitis caused by nontuberculous mycobacteria (NTM) in children. A blood test is a faster and more comfortable way to confirm a diagnosis than invasive procedures, such as a biopsy.
Merparten av hjärnskadorna vid elsparkcykelolyckor inträffade under berus-ning – begränsningar minskade olyckorna avsevärt30.6.2026 09:26:42 EEST | Pressmeddelande
A study by HUS and the University of Helsinki shows that more than 80 percent of traumatic brain injuries related to electric scooter use occurred while under the influence of alcohol. The majority of accidents occurred on weekend nights. Restrictions on e-scooter use have significantly reduced the incidence of traumatic brain injuries.
Suurin osa sähköpotkulautailun aiheuttamista aivovammoista sattui humalassa – rajoitukset vähensivät tapaturmia merkittävästi30.6.2026 09:26:42 EEST | Tiedote
HUSin ja Helsingin yliopiston tutkimus osoittaa, että yli 80 prosenttia sähköpotkulautailuun liittyvistä aivovammoista sattui alkoholin vaikutuksen alaisena. Valtaosa tapaturmista sattui viikonloppuöisin. Käyttörajoitusten myötä aivovammojen ilmaantuvuus väheni merkittävästi.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
